Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis

Chuma, M; Uojima, H; Hattori, N; Arase, Y; Fukushima, T; Hirose, S; Kobayashi, S; Ueno, M; Tezuka, S; Iwasaki, S; Wada, N; Kubota, K; Tsuruya, K; Shimma, Y; Hiroki, I; Takuya, E; Tokoro, C; Iwase, S; Miura, Y; Moriya, S; Watanabe, T; Hidaka, H; Morimoto, M; Numata, K; Kusano, C; Kagawa, T; Maeda, S

Chuma, M (通讯作者)，Yokohama City Univ, Gastroenterol Ctr, Med Ctr, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.

HEPATOLOGY RESEARCH, 2022; 52 (3): 269

Abstract

Purpose To assess the impact of clinical factors on the safety and efficacy of atezolizumab plus bevacizumab (ATZ + BV) treatment in patients with unr......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索